1368605-53-1 Usage
Description
[1-(3-chloro-4-fluorophenyl)cyclopropyl]methanamine is a cyclopropylmethanamine derivative featuring a 3-chloro-4-fluorophenyl substituent. It belongs to the cyclopropylamine class and is recognized for its unique structure and properties, which make it a valuable asset in the field of medicinal chemistry and drug discovery. [1-(3-chloro-4-fluorophenyl)cyclopropyl]methanamine is primarily utilized as a building block in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of novel treatments and products.
Uses
Used in Pharmaceutical Research:
[1-(3-chloro-4-fluorophenyl)cyclopropyl]methanamine is used as a building block for the synthesis of pharmaceuticals due to its unique structure and properties. It aids in the development of new drugs by providing a foundation for chemical modifications and enhancements, potentially leading to improved therapeutic effects and reduced side effects.
Used in Agrochemical Research:
Similarly, in the agrochemical industry, [1-(3-chloro-4-fluorophenyl)cyclopropyl]methanamine is used as a building block for the synthesis of various agrochemicals. Its application in this field helps in the creation of innovative products that can enhance crop protection, yield, and overall agricultural productivity.
Check Digit Verification of cas no
The CAS Registry Mumber 1368605-53-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,8,6,0 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1368605-53:
(9*1)+(8*3)+(7*6)+(6*8)+(5*6)+(4*0)+(3*5)+(2*5)+(1*3)=181
181 % 10 = 1
So 1368605-53-1 is a valid CAS Registry Number.
1368605-53-1Relevant articles and documents
Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation
Stama, Madia Letizia,?lusarczyk, Joanna,Lacivita, Enza,Kirpotina, Liliya N.,Schepetkin, Igor A.,Chamera, Katarzyna,Riganti, Chiara,Perrone, Roberto,Quinn, Mark T.,Basta-Kaim, Agnieszka,Leopoldo, Marcello
, p. 703 - 720 (2017)
Formyl peptide receptor2 (FPR2) is a G-protein coupled receptor that plays critical roles in inflammatory reactions. FPR2-specific interaction can be possibly used to facilitate the resolution of pathological inflammatory responses by enhancing endogenous anti-inflammation systems. Starting from our lead agonist 5, we designed new ureidopropanamides derivatives able to activate FPR2 in transfected cells and human neutrophils. The new FPR2 agonists showed good stability towards oxidative metabolism in vitro. Moreover, selected compounds showed anti-inflammatory properties in LPS-stimulated rat primary microglial cells. (S)-3-(4-Cyanophenyl)-N-[[1-(3-chloro-4-fluorophenyl)cyclopropyl]methyl]-2-[3-(4-fluorophenyl)ureido]propanamide ((S)-17) emerged as prospective pharmacological tool to study the effects of FPR2 activation in the central nervous system (CNS) being able to reduce IL-1β and TNF-α levels in LPS-stimulated microglial cells and showing good permeation rate in hCMEC/D3 cells, an in vitro model of blood brain barrier. These results are very promising and can open new therapeutic perspectives in the treatment of CNS disorders characterized by neuroinflammation.
